Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00KDQ
|
|||
| Drug Name |
Anti-CEA CAR-T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 1 | [1] | |
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 1 | [1] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 1 | [1] | ||
| Peritoneal metastasis [ICD-11: 2D91] | Phase 1 | [1] | ||
| Company |
Sorrento Therapeutics, Inc.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | CAR-T-Cell-Therapy | [1] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.